94 27. Akkerman ATJWN, Analyzer- PF, Voor VW, et al. Betekenis van de ‘ Platelet Function Analyzer-100 ® ’ in de dagelijkse diagnostiek. Nederlands Tijdschrift voor Hematologie 2006; 3: 133–7. 28. Sadler JE. Von Willebrand disease type 1: A diagnosis in search of a disease. Blood 2003; 101: 2089–93. 29. McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta. J Clin Pathol 1996; 49: 627–30. 30. Alves GSA, Orsi FA, Santiago-Bassora FD, et al. Laboratory evaluation of patients with undiagnosed bleeding disorders. Blood Coagulation & Fibrinolysis 2016; : 1. 31. Hayward CPM. How I investigate for bleeding disorders. 2018; 40: 6–14. 32. Goddeau RP, Caplan LR, Alhazzani AA. Intraparenchymal hemorrhage in a patient with osteogenesis imperfecta and plasminogen activator inhibitor-1 deficiency. Arch Neurol 2010; 67: 236–8. 33. Mao L, Kawao N, Tamura Y, et al. Plasminogen Activator Inhibitor-1 Is Involved in Impaired Bone Repair Associated with Diabetes in Female Mice. 2014; 9: 3–10. 34. Moritake A, Kawao N, Okada K, et al. Plasminogen activator inhibitor-1 deficiency enhances subchondral osteopenia after induction of osteoarthritis in mice. 2017; : 1–8. 35. Jin G, Aobulikasimu A, Piao J, et al. A small-molecule PAI-1 inhibitor prevents bone loss by stimulating bone formation in a murine estrogen deficiency-induced osteoporosis model. FEBS Open Bio 2018; 8: 523–32. 36. Iris Schvartz, Dalia Seger SS. Vitronectin. The International Journal of Biochemistry & Cell Biology 31 1999; 31: 539–44.
RkJQdWJsaXNoZXIy MTk4NDMw